GDNF and Parkinson disease: The ICV delivery route was used, even though the sponsor’s own data demonstrated very limited penetration into brain following ICV administration [79], as shown in Figure 5C. For the reasons discussed in Section 2.1.4, the failure of the ICV trial of GDNF for PD was expected.